NIH Conference Charts Future Directions in Identifying Patients at Risk for Primary Pulmonary Hypertension

2003 ◽  
Vol 2 (3) ◽  
pp. 4-5

This report is based on information presented at a conference sponsored by the National Institutes of Health (NIH) earlier this year to identify trends in diagnosis and management of the disease.

2009 ◽  
Vol 8 (6) ◽  
pp. 569-580 ◽  
Author(s):  
Jean Marie U-King-Im ◽  
Victoria Young ◽  
Jonathan H Gillard

US Neurology ◽  
2010 ◽  
Vol 05 (02) ◽  
pp. 52
Author(s):  
Glen Jickling ◽  
Huichun Xu ◽  
Frank Sharp ◽  
◽  
◽  
...  

The diagnosis and management of patients with ischemic stroke is primarily based on clinical assessment in conjunction with imaging tests. Development of molecular biomarkers as additional tools to support a clinical diagnosis, identify patients at risk of disease, and help guide patient treatment and prognosis would be of great value. Currently, no such biomarkers are used in the management of patients with ischemic stroke; however, several promising proteomic and genomic markers have been identified, as presented in this review.


Author(s):  
Philipp Douschan ◽  
Vasile Foris ◽  
Alexander Avian ◽  
Teresa Sassmann ◽  
Horst Olschewski ◽  
...  

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 137S
Author(s):  
Chirag M. Pandya ◽  
Omar A. Minai ◽  
J.A. Golish ◽  
K. McCarthy ◽  
J. Avecillas ◽  
...  

Author(s):  
Vasile Foris ◽  
Florian Prüller ◽  
Gabor Kovacs ◽  
Alexnder Avian ◽  
Philipp Douschan ◽  
...  

2018 ◽  
Vol 46 (2) ◽  
pp. 176-183 ◽  
Author(s):  
Vivien M. Hsu ◽  
Lorinda Chung ◽  
Laura K. Hummers ◽  
Ami Shah ◽  
Robert Simms ◽  
...  

Objective.We sought to identify predictors of mortality and cardiopulmonary hospitalizations in patients at risk for pulmonary hypertension (PH) and enrolled in PHAROS, a prospective cohort study to investigate the natural history of PH in systemic sclerosis (SSc).Methods.The at-risk population for PH was defined by the following entry criteria: echocardiogram systolic pulmonary arterial pressure > 40 mmHg, or DLCO < 55% predicted or ratio of % forced vital capacity/%DLCO > 1.6, measured by pulmonary function testing. Baseline clinical measures were evaluated as predictors of hospitalization and death between 2005 and 2014. Cox proportional hazards models were censored at date of PH onset or latest study visit and adjusted for age, sex, race, and disease duration.Results.Of the 236 at-risk subjects who were followed for a median of 4 years (range 0.4–8.5 yrs), 35 developed PH after entering PHAROS (reclassified as PH group). In the at-risk group, higher mortality was strongly associated with male sex, low %DLCO, exercise oxygen desaturation, anemia, abnormal dyspnea scores, and baseline pericardial effusion. Risks for cardiopulmonary hospitalization were associated with increased dyspnea and pericardial effusions, although PH patients with DLCO < 50% had the highest risk of cardiopulmonary hospitalizations.Conclusion.Risk factors for poor outcome in patients with SSc who are at risk for PH were similar to others with SSc-PH and SSc-pulmonary arterial hypertension, including male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions. This group should undergo right heart catheterization and receive appropriate intervention if PH is confirmed.


2018 ◽  
Vol 16 (3) ◽  
pp. 136-140 ◽  
Author(s):  
Anna R. Hemnes

“A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker or signature molecule” – Biomarker definition, National Institutes of Health, National Cancer Institute, Dictionary of Cancer Terms Although this definition pertains to the field of cancer and cancer biology, it applies to many disciplines, including the field of pulmonary vascular disease. In the world of pulmonary hypertension (PH), biomarkers hold a special place. In the diagnosis of PH subtype, we are limited by the risk of lung biopsy1 and, further, in patients with pulmonary arterial hypertension (PAH) we are limited by the inability to frequently obtain our strongest predictors of mortality: invasive pulmonary hemodynamic assessment. Thus, biomarkers hold much promise for the field of PH. We are searching for markers of PH subtypes and endophenotypes. We are looking for predictors of mortality in all forms of PH and, critically, we are hoping to find peripheral blood markers that will help us discover which drugs are likely to benefit a particular patient. Although we have made inroads in all 3 areas, there are substantial opportunities for refinement of our current biomarkers and discovery of novel markers to improve the care of PH patients. This review will cover the state of current biomarkers in PH and discuss challenges and future directions.


2021 ◽  
Vol 26 ◽  
Author(s):  
Vidit N. Munshi ◽  
Soroush Saghafian ◽  
Curtiss B. Cook ◽  
Sumhith Veda Aradhyula ◽  
Harini A. Chakkera

Sign in / Sign up

Export Citation Format

Share Document